Abstract
The purine nucleoside analogs fludarabine and 2-chloro-2'-deoxyadenosine display substantial activity in the treatment of various chronic lymphoproliferative disorders. Their major toxicities are primarily immunosuppression and myelosuppression. The profound influence of these drugs on the immune system has raised questions as to the emergence of secondary neoplasms or auto-immune disorders after their use. Based on a literature review and on personal observations, this article reviews the potential clinical importance of these concerns.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / immunology
-
Antineoplastic Agents / therapeutic use
-
Autoimmunity
-
Cladribine / adverse effects*
-
Cladribine / immunology
-
Cladribine / therapeutic use
-
Humans
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / immunology
-
Immunosuppressive Agents / therapeutic use
-
Neoplasms / drug therapy*
-
Neoplasms / immunology
-
Neoplasms / pathology
-
Neoplasms, Second Primary / etiology*
-
Neoplasms, Second Primary / immunology
-
Vidarabine / adverse effects*
-
Vidarabine / analogs & derivatives
-
Vidarabine / immunology
-
Vidarabine / therapeutic use
Substances
-
Antineoplastic Agents
-
Immunosuppressive Agents
-
Cladribine
-
Vidarabine
-
fludarabine